Literature DB >> 7577049

The value of adjuvant radio(chemo)therapy for rectal cancer.

L Påhlman1, B Glimelius.   

Abstract

Radiotherapy has been used extensively as an adjuvant treatment with surgery for patients with rectal cancer. Present knowledge indicates that preoperative radiotherapy is more dose-efficient than postoperative radiotherapy in reducing local recurrence rate. Provided the dose is sufficiently high, the reduction exceeds 50% in all Dukes' stages and after both abdominal perineal excision and anterior resection. The effect on survival has not yet been proven but there are indications that survival may be slightly improved using preoperative radiotherapy, although the magnitude of this improvement is probably less than with postoperative chemotherapy. Of concern with all adjuvant treatments are the potential side-effects, and it appears that postoperative radiotherapy has more side-effects than preoperative radiotherapy, even if the reduction of local recurrences is less and proper radiation techniques are utilised.

Entities:  

Mesh:

Year:  1995        PMID: 7577049     DOI: 10.1016/0959-8049(95)91268-h

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial.

Authors:  M Dahlberg; B Glimelius; L Påhlman
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

2.  Quantitative assessment of tumor responses after radiation therapy in a DLD-1 colon cancer mouse model using serial dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Sung Jun Ahn; Woong Sub Koom; Chan Sik An; Joon Seok Lim; Seung-Koo Lee; Jin-Suck Suh; Ho-Taek Song
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

3.  MRI and its importance in rectal cancer.

Authors:  R J Heald
Journal:  Cancer Imaging       Date:  2000-10-09       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.